

Review Article

EPIDEMIOLOGIC REVIEW OF ZIKA VIRUS DISEASE

¹Shwe DD, ²Shehu N, ⁴Pam VC, ³Keneth O, ²Gomerep S, ³Isa SE, ¹Yilgwan CS, ⁴Okolo OJ, ¹Abok II, ⁵Obishakin ET, ⁴Egah DZ, ¹Oguche S.

¹Department of Paediatrics, Jos University Teaching Hospital/Faculty of Medical Sciences, University of Jos.

²Department of Internal Medicine, Jos University Teaching Hospital

³Department of Obstetrics and Gynaecology Jos University Teaching Hospital/Faculty of Medical Sciences, University of Jos

⁴Department of Medical Microbiology, Jos University Teaching Hospital/Faculty of Medical Sciences, University of Jos

⁵Department of Molecular Biology/Immunology, National Veterinary Research Institute, Vom, Plateau State, Nigeria.

SUMMARY

Zika virus disease has resonated great concern globally. The World Health Organization declared it “a public health emergency of International concern” on 1st February, 2016. The recent outbreaks have become a major challenge due to a drift from its earlier known benign exanthematous spectrum to a causal link to microcephaly. Historically, the name Zika virus comes from the Zika Forest of Uganda. It was first identified in 1947 among Rhesus Macaque sub-population. Two genetically distinct isolates have been well characterized; the Asian and African strains. This virus is spread by bites of day-time-active *Aedes* mosquitoes; the *Aedes aegypti* and *Aedes albopictus*. Zika Virus appears to spread along a narrow equatorial belt of Africa to Asia through the Pacific Ocean to French Polynesia, New Caledonia (southwest Pacific Ocean), the Cook Islands (south Pacific), and Easter Island (a Chilean territory in Polynesia), and most recently to Mexico, Central America, the Caribbean, and South America, where today has assumed a pandemic proportion.

Up to eighty percent of infections are asymptomatic. Symptomatic infections are characterized by a self-limiting febrile illness and maculopapular rash, arthralgia, conjunctivitis, back pain and mild headaches. Maternal Zika viral load is thought to be a significant risk factor to fetal infection leading to invasion of either trophoblasts or placental cells or both through maternal decidua. Zika viral RNA proteins and associated extensive selective tissue injuries have been demonstrated in the brains and spinal cords of abortuses. Diagnosis of Zika virus is essentially based on viral RNA detection from clinical specimens. Currently, licensed preventive medicines or vaccines are unavailable. With the wide spate of recent outbreaks and consequent neurologic morbidity and mortality, there is need for deployment of point-of-care equipment for screening of pregnant women in our environment. This is an ambitious call for advocacy by all relevant health care providers.

Key words: Zika Virus, disease outbreaks, microcephaly, *Aedes* mosquitoes.

NigerJmed2018: 180-187

© 2018. Nigerian Journal of Medicine

INTRODUCTION

Zika virus fever is an arthropod-borne viral infection caused by Zika virus.¹ It is a Flavivirus from Flaviviridae family. Historically, its name comes from the Zika Forest of Uganda in East Africa where it was first identified in 1947, among the Rhesus Macaque sub-population.² Two genetically distinct isolates have been characterized; the Asian and African strains.²⁻⁴

The Zika virus is spread by bites from daytime-active *Aedes* mosquitoes; *A. aegypti* and *A. albopictus*.⁵ From the nineteen-fifties, this virus has been known to spread characteristically eastward and appears to

do so within a narrow equatorial belt from Africa to Asia through the Pacific Ocean to French Polynesia, New Caledonia (southwest Pacific Ocean), the Cook Islands (south Pacific), and Easter Island (a Chilean territory in Polynesia), and most recently to Mexico, Central America, the Caribbean, and South America, where today has assumed a pandemic proportions.⁶

A population based-survey in 1947 in Uganda found a prevalence of 6.1%.⁷ Another sero-prevalence survey among healthy population in sub-urban community in Indian found substantial antibodies to Zika virus, suggesting a prior exposure.⁸ The first reported human case of Zika virus infection in Nigeria was in 1954.⁹ In a population based study which included 60% pregnant women in north-central Nigeria,

Corresponding author: Shwe, David Danjuma
Department of Paediatrics, Jos University Teaching Hospital/
Faculty of Medical Sciences, University of Jos.

E-mail: shwedavid@yahoo.com

Tel: +234 816 348 0425

(2018), Phillip *et al* found an anti-ZIKV positive rate of 6% for IgM and 4% for IgG. Pregnant women showed antiZIKV positive rates of 4% for IgM and 3% for IgG. A significant association with male sex was found for anti-ZIKV IgG ELISA positivity (prevalence ratio 3.49; 95% CI: 1.48–8.25; $p=.004$). In the same study, ZIKV neutralizing antibodies were detected in 17 / 18 (94%) anti-ZIKV NS1 positive/borderline samples and in one sample without detectable ZIKV NS1 antibodies. Partial ZIKV E gene sequence was retrieved in one sample without ZIKV antibodies, which clustered within the West African ZIKV lineage.¹⁰

The virus may be transmitted vertically from an infected pregnant mother to her unborn baby. This intra-uterine infection has recently been causally associated with microcephaly. Infection in adult sub-population may also result in Guillain-Barre syndrome.¹¹ Currently, prevention medicines and vaccines against Zika virus fever does not exist.¹²

With increased global travels for economic, medical and social tourisms, no country of the world is immune to this infectious virus. While there are plethora of literature and ongoing research efforts on the Zika virus infection in some parts of the world, same cannot be said in our setting. The aim of this article therefore, is to provide an epidemiological review of Zika Virus Disease and to highlight relevant lessons that could be learnt from previous Zika virus outbreaks in regard to epidemic preparedness.

Documented outbreaks

The discovery of Zika virus was rather an incidental finding. In April, 1947, a team of scientists of the Yellow Fever Research Institute first isolated a filterable transmissible infectious particle from serum of a febrile rhesus macaque monkey which had been placed in a cage in the Zika Forest of

Uganda near Lake Victoria.¹³ This team of researchers at the time was working on Yellow Fever Virus project.¹³ A second viral isolation was subsequently made in January, 1948 from *Aedes africanus* among the same sub-populations of febrile monkeys.^{14,15}

The first evidence suggestive of human Zika virus infection

Historically, Zika virus has been known to infect human subjects from previous serological surveys in Uganda and Nigeria: Fifty of 84 cohort screened for Zika virus were seropositive and all of who were over 40 years of age.¹⁴ A similar survey amongst Indian natives demonstrated strong immunogenicity. Both studies cited above suggests widespread Zika virus infection in human population.¹⁶

In 1952, a team of scientists was investigating a suspected Yellow Fever outbreak in a 10-year old Nigerian female who had fever, headaches, joint pain but no jaundice and had recovered spontaneously from her illness within few days. Her blood was injected into the brain of a laboratory mice. The virus isolates from the mouse brain was then tested for neutralizing specific antibodies to Zika virus using rhesus monkey sera. Curiously, no virus was isolated from the blood of two infected adults with fever, jaundice, cough, diffuse joint pains in one of the adults and fever, headaches, and arthralgia. Zika virus infection was then isolated in human for the first time. In 1954, the finding was published.¹⁷

Zika virus spread in Equatorial Africa and Asia, 1952 to 1983

Between 1951 and 1983, clinical and laboratory evidence of human Zika virus were subsequently reported from other African countries like the Central African Republic, Egypt, Gabon, Sierra Leon, Tanzania and Uganda. Similar reports were documented in other parts of Asia such as India, Malaysia, the Pakistan, Philippines,

Vietnam and Thailand.^{18,19} As at 2007, fourteen countries had confirmed human cases of Zika fever from continents of Africa and South-East Asia.²⁰

ZVD Outbreak in Micronesia, 2007

The first and major reported outbreak of Zika fever outside the continents of Africa and Asia was in April, 2007 on the Yap Island Federation, Micronesia. The commonest clinical manifestations were fever, skin rash, arthralgia and conjunctivitis.²¹ These symptomatology was previously considered to be dengue, Chikungunya or the Ross River disease. However, during the acute phase of the disease, 108 Zika RNA seropositive by PCR or serology and 72 additional suspect cases. No morbidity or mortality from ZVD was recorded.²²

The predominant mosquito vector spp. identified was *Aedes hensilli*. While the mode of introduction of the Zika fever had remained elusive, it was thought to have happened through infected mosquitoes or a human infected with related strains from the Southeast Asia.²³

Oceania ZVD outbreak of 2013 to 2014

Between 2013 and 2014, pockets of Zika fever outbreaks were reported. Among those were in the French Polynesia, Easter Island, New Caledonia and the Cook Islands. The virus source of this outbreak was not immediately clear. It was however, thought to be an independent introduction from those of the Southeast Asia which was linked to the Yap Island outbreak described above.²⁴

The Americas: Zika virus Outbreak from 2015 to date

In February 2014, Zika virus outbreak was reported throughout South and Central America, and by November of 2015, it had reached Mexico.²⁵ Ten confirmed cases of Zika travel-related infections were reported in Dallas and Texas, United States of America and Europe without identifiable mosquito vectors.²⁶ Sexual transmission of Zika virus

was reported almost for the first time in Texas in February 2016.^{25,27}

Brazilian health authorities reported its first 16 cases of Zika fever in 14 states of the country as at May, 2015.²⁸ By December 12, 2015, the Brazilian Ministry of Health reported about 2,400 suspected cases of microcephaly in the country, of which 29 cases resulted in mortality.²⁹⁻³¹ In the State of Pernambuco alone, cases of microcephaly had exponentially rose from 150 to 200 per year the preceding 5 years.³² A mathematical model estimated the risk of microcephaly to 1% of all infants born to Zika virus seropositive mothers in the first trimester of pregnancy.³³

On January 2016 WHO issued a public health warning of possible Zika virus spread to contiguous countries of the Americas because of the bionomics of the *Aedes* mosquito vector.³⁴ By February, 2016, it declared Zika virus a Public Health Emergency of International Concern because of compelling evidence of pregnancy loss, birth defects and other neurological deficits.³⁵ In April 2016, there was an expert consensus on Zika related microcephaly and Guillain-Barre syndrome in human adult.^{36,37}

Aetiology of ZVD

Zika fever is caused by Zika virus. It is an envelope, icosahedral, non-segmented single-stranded, positive-sense RNA virus, a flavivirus from the Flaviviridae family. Viral particles are 40nm in diameter with an outer envelope and a dense inner core^{38,39,40} Thus, it is related to dengue, yellow fever, Japanese encephalitis and West Nile virus.

Transmission

Zika virus disease is predominantly spread through the bite of infected female *Aedes* mosquito.⁴¹ An infected male can transmit the virus to his sex partner. Sexual transmission has been reported in 6 countries: Argentina, Chile, France, Italy, New Zealand and the

United States of America in 2015¹¹ Zika virus transmission via blood and blood products transfusions have also been documented.⁴² In April, 2016, 2 cases were reported both from Brazil. ⁴³Transplacental spread from an infected pregnant mother to her unborn baby or at delivery (birth canal) have been recognized^{11,44}

The *Aedes* mosquito vector is very active during day time. It breeds around stagnant water, abandon automobile parts, flower vases, uncovered buckets and wet shower flows. Only the female bites for blood, required to mature her eggs. Characteristically, she bites 4 to 5 times a day in the afternoon and early in the evenings. There are two types: the *Aedes aegypti* and *Aedes albopictus*.⁴⁵

Pathogenesis

Zika virus replicates in the epithelial lining of the mid-gut and the salivary cells of mosquito vector. After a variable period of about 5 days, it appears in the mosquito saliva which subsequently becomes infectious. During blood meal, the vector inoculates its human host skin. The virus may then infect the epidermal keratinocytes, the fibroblast and the Langerhans cells. It is thought that, the Zika virus spreads to the lymphatic and haematogenously.^{3,8,46} In stark contrast to other Flaviviruses, its antigen has been demonstrated in host cell nucleic.⁴⁶

Clinical features

Up to eighty per cent of infections are asymptomatic.⁴⁸ Symptomatic (viraemic stages) of infections are characterized by a self-limiting febrile illness of 4-7 days duration associated by maculopapular rash, arthralgia, conjunctivitis, back pain and mild headaches. Within 2 days, skin rash begin to fade spontaneously and within 3 days, fever starts to resolve and only few rash persists.⁴⁹

Maternal Zika viral load is thought to be a significant risk factor to fetal infection. The

mechanism for intra-uterine infection is not completely clear. It is thought that, maternal Zika viraemia is critical to invasion of either trophoblasts or placental cells or both through maternal decidua. Zika virion then binds to maternal intervillous spaces by a process of transcytosis to yet unidentified receptors. It said to now replicates more efficiently in FcyR in myeloid cells. Zika viral RNA proteins and associated extensive selective tissue injuries have been demonstrated in the brains and spinal cords of abortuses.⁵⁰

Gullain-Barre syndrome is thought to be due to immunopathology resulting from antigenic mimicry of a host protein. Zika virus appears to have selective tropism to neurons/glia cells causing demyelination of affected neurons. Frequently reported clinical manifestations include: muscle weakness, tingling sensations on the arms and legs and parasthesias. Recently, a positive association has been observed with prior or concurrent Dengue virus infections.⁴⁵

Some yet unanswered pathogenetic questions about Zika virus disease; are there sanctuary sites for Zika virus in human host? What is the nature of pathologic lesions of the virus and why only certain individual human hosts manifest the disease? Detailed longitudinal studies are needed to answer such questions.⁵¹

Ultrasonographic findings at 18 to 19 week's gestation suggestive of Zika virus infection include cerebral hemispheres were markedly asymmetric (severe unilateral ventriculomegaly) - almost complete disappearance or failure to develop the thalami - thin pons and brainstem Mother.⁵⁰ By the 29 weeks intra-uterine life, observed changes become evident such as microcephaly, brain atrophy with coarse calcifications involving the white matter of the frontal lobes, the caudate nucleus, lentostriatal vessels and the cerebellum. Other notable sonographic anomalies are

dysgenesis of the vermis and corpus callosum and enlargement of the cisterna magna.⁵¹

Laboratory Diagnosis

Diagnosis of Zika virus is essentially based on viral RNA detection from clinical specimens. Direct virus detection is only during the first 3 to 5 days after onset of symptoms.^{1, 52, 53} Specific assays targeting the Asian and African Zika virus isolates of the envelope gene or NS5 region^{1,52} Pan-flavivirus assays and sequencing analysis can be used as a surrogate for possible Zika virus infection^{53,54}

Saliva and urine specimens for viral genome detection by RT-PCR might be diagnostic. ZIKV-specific IgM/IgG antibodies can be detected by ELISA and immunofluorescence assays in serum specimens, usually from day five or six of symptomatic illness.

False positive test results may be with dengue and other Flavivirus infections. A positive result for dengue IgM antibodies without detection of dengue IgG in paired sera among travellers returning from areas affected by ZIKV should prompt a possible investigation for another flavivirus aetiology. Positive results should be confirmed by neutralization test.

Treatment

At the moment, no preventive medicines or vaccines are available. However, Zika virus disease symptoms may be controlled with bed rest, intravenous fluids and acetaminophen⁵⁵

Vaccine development

As at January 2016, the NIH Vaccine Research Center started some work toward s development of effective vaccine for Zika.⁵⁶ In February, 2016, Bharat Biotech International announced it was developing 2 candidate vaccines; recombinant and inactivated Zika vaccines, both of which are at preclinical stages of development.⁵⁷ eighteen

international companies as at March, 2016 have been working very hard to produce vaccines against Zika virus, but known had reached clinical trials⁵⁸

CONCLUSION

With wide distribution of competent *Aedes aegypti* and *Aedes albopictus* mosquito vectors in the Americas, some European countries, sub-saharan Africa including Nigeria, the unfortunate absence of available vaccines globally, ZIKV Disease spread is likely to continue for some time. These possibilities are significantly made even easier by increased global travels for both economic and tourism purposes. The causal link of ZIKV infection to abortion, microcephaly and other Central Nervous System anomalies has further made it even urgent for coordinated effort by health authorizes of other seeming Zika-free countries to set up surveillance and containment strategies in countries where the *Aedes* mosquito vectors are equally abundant. In addition, deployment of point-of-care equipment for screening of pregnant women in antenatal clinics may be helpful in our environment. This, is an ambitious call for advocacy by all relevant health care providers.

Conflict of interest disclosure: Authors have no financial conflict or conflict of commitment to disclose.

REFERENCES

1. Balm MN, Lee CK, Chiu L, Koay ES, Tang JW. A diagnostic polymerase chain reaction assay for Zika virus. *J Med Virol.* 2012 September 84 (9): 1501-5
2. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus Flavivirus. *J virol*, 1998 Jan; 72(1):73-83
3. Oumar F, Caio CMF, Atila I, Ousmane F, Juliana VCO, Mawlouth D, et al. Molecular Evolution of Zika Virus during Its Emergence in the 20th Century. *PLoS Negl Trop Dis.* 2014;8(1):e2636.
4. Haddow AD, Schuh AJ, Yasuda CY, Kassper MR, Heang V, Huy R, et al. Genetic characterization of Zika virus strains: Geographic Expansion of the Asian lineage. *PLoS. Negl Trop Dis.* 2012;6(2):e1477.

5. Malone RW, Jane H, Michael VC, Jill G, Lambodhar D, Adriano DBS, et al. Zika Virus: Medical Countermeasure Development Challenges. *PLOS Negl Trop Dis* March 2016; 10 (3) : e 0 0 0 4 5 3 0 . doi:10.1371/journal.pntd.0004530. ISSN 1935-2735.
6. Chastain M. 'National Institutes of Health: Zika Virus Is a Pandemic. *Breitbart*; January 2016. Accessed February 2016.
7. Centers for Disease Control and Prevention. All Countries and Territories with Active Zika Virus Transmission". April 2016. Accessed April 2017
8. Smithburn, KC, Kerr JA, Gatne PB. "Neutralizing antibodies against certain viruses in the sera of residents of India. *J Immunol*, April 1954, Baltimore, Md.: 1950) 72 (4): 248–257. PMID 13163397.
9. MacNamara, F.N. Zika virus: A report on three cases of human infection during an epidemic of jaundice in Nigeria. *Trans R Soc Trop Med Hyg* 1954 48 (2): 139–145. doi:10.1016/0035-9203(54)90006-1. ISSN 0035-9203.
10. Phillip M, Daniel ZE, Janis AM, NathanYS, Emmanuel TO, David DS et al: Low Zika virus seroprevalence among Pregnant women in north central Nigeria, 2016: (2018), *J Clin Virol* 105, 35–40. Available at: <https://doi.org/10.1016/j.jcv-2018.05.011>
11. World Health Organization. 7 April 2016. Accessed April 2016. Zika Virus Microcephaly And Guillain-Barré Syndrome Situation Report Pdf
Centers for Disease Control and Prevention
12. Zika virus. Atlanta: Symptoms, Diagnosis, & Treatment". 3 March 2016. Retrieved 4 March 2016.
13. Cohen Jon. 'Zikas long, strange trip into the limelight. February 2016, *Science* (American Association for the Advancement of Science). Retrieved 10 February 2016.
14. Hayes EB. Zika Virus Outside Africa. *Emerging Infectious Diseases* September 2009,15 (9): 1347–1350. doi:10.3201/eid1509.090442. ISSN 1080-6040. PMC: 2819875. PMID 19788800.
15. Pro-MED-mail. International Society for Infectious Disease. Zika Virus (06): Overview 2016-02-09 19:58:3 Archive Number: 20160209.4007411.
16. Rowlatt J. Why Asia should worry about Zika too". February 2016, *BBC News*. Accessed February 2016.
17. Dick GWA, Kitchen SF, Haddow AJ. Zika Virus 1. Isolations and serological specificity. *Trans R Soc Trop Med Hyg* September 1952, 46 (5): 509–520. doi:10.1016/0035-9203(52)90042-4. ISSN 0035-9203. PMID 12995440
18. Hayes EB. Zika Virus Outside Africa". *Emerging Infectious Diseases*, September 2009, 15 (9): 1347–1350. doi:10.3201/eid1509.090442. ISSN 1080-6040. PMC: 2819875. PMID 19788800. Timeline-Zika's origin and global spread
19. Fox News, March 2016. Accessed March 2016.
20. Ramzy A, 'Experts Study. Zikas Path From First Outbreak in Pacific, February 2016. *The New York Times* (Hong Kong). Accessed February 2016.
21. Altman LK, Little-Known Virus Challenges a Far-Flung Health System; July 2007, *New York Times*., Accessed online 2016.
22. Mark RD, Tai-HO C, HancockWT, Ann NP, Jacob LK, Robert SL, et al. Zika Virus Outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med* June 2009, 360 (24): 2536–2543. doi:10.1056/NEJMoa0805715. ISSN 0028-4793. PMID 19516034.
23. CDC. All Countries and Territories with Active Zika Virus Transmission; April 2016. Accessed 15 April 2016.
24. Gatherer D, Kohl A. Zika virus: a previously slow pandemic spreads rapidly through the Americas. *J Gen Virol* December 2015,97 (2): 269–273. doi:10.1099/jgv.0.000381. PMID 26684466.
25. Sikka V, Chattu VK, Popli RK, Galwankar SC, Kelkar D, Sawicki SG, et al. The emergence of zika virus as a global health security threat: A review and a consensus statement of the INDUSEM Joint working Group (JWG). *J Global Infect Dis* 2016;8:3-15 Wade, Carla (8 February 2016). "DCHHS: 10 Zika cases reported in Texas". WFAA (Dallas). Retrieved 9 February 2016.
26. Alexandra MO, Kate R, Jo ES, Allison F, Rachel EK, Emily EPet al., Ministry of Health confirms 8 cases of zika virus in infants May 2015. <http://www.bbc./portugues/notice/2015/11>
27. CDC, Monitoring cases of microcephaly in Brazil pdf, 12 December 2015. Accessed December 2015. Available at <http://www.portal/saude.gov.br/images/pdf/2015>
Government confirms relationship between zika virus and epidemic microcephaly]
28. BBC Brasil; November 2015. Accessed March 2016. Accessed at <http://www.bbc/portugues/notice/2015>
29. Blount J. Brazil confirms zika virus link to fetal brain-damage outbreak. November 2015 *Reuters*. Retrieved February 2016. Accessed at <http://www.reuters.com/article/brazil-health-zika-indust-in13n0nh2015112>
30. European Centre for Disease Prevention and

- Control. Rapid risk assessment: Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barré syndrome December 2015. Available at; <https://ecdc.europa.eu/sites/portal/files/media/en/publications/zika-virus-americas-with-rapid-risk-assessment.pdf>. Accessed February 2016.
31. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot, D, et al. -Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. *The Lancet*. doi:10.1016/s0140-6736(16)00651-6.
 32. Walter Reed Biosystematics Unit *Aedes luteocephala*. Medically Important Mosquitoes. Accessed February 2016.
 33. Pearson M. Zika virus sparks 'public health emergency'. CNN. February 2016.
 34. Rosen, M. Science News. *Soc Public Sci*; January 2016;189 (4): 16. Accessed February 2016.
 35. World Health Organization. Zika Virus Microcephaly And Guillain-Barré Syndrome: Situation Report (pdf). April 2016. Accessed April 2016.
 36. Goldsmith, C. Zika Virus. Centers for Disease Control and Prevention. March 2005. Accessed March 2016.
 37. Knipe DM, Howley PM. *Fields' Virology* (5th ed.). In: Lippincott Williams & Wilkins. 2007 p 1156, 1199. ISBN 978-0-7817-6060-7.
 38. Oumar F, Freire CCM, Atila I, Faye O, de Oliveira JVC, Mawlouth D, et al. Molecular Evolution of Zika Virus during Its Emergence in the 20th Century. *PLoS Negl Trop Dis* January 2014 8 (1): e2636. doi:10.1371/journal.pntd.0002636. PMC: 3888466. PMID 24421913.
 39. Chen LH, Hamer DH. Zika Virus: Rapid Spread in the Western Hemisphere. *Ann Int Med*. 2016 doi:10.7326/M16-0150. ISSN 0003-4819
 40. Oster AM, Russell K, Stryker JE, Friedman A, Kachur RE, Petersen EE et al. Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus – United States, MMWR. *Morbidity and Mortality Weekly Report* April 2016;65 (12): 323–325. doi:10.15585/mmwr.mm6512e3. PMID 27032078.
 41. CDC – Survey of Blood Collection Centers and Implementation of Guidance for Prevention of Transfusion-Transmitted Zika Virus Infection Puerto Rico, 2016 Brazil reports Zika infection from blood transfusions. February 2016. In: *MMWR Early Release*, April 2016, 65. CDC Zika: Transmission
 42. U.S. Centers for Disease Control and Prevention. 15 April 2016. Accessed April 2016.
 43. Chan JFW, Choi Garnet KY, Yip CCY. Zika fever and congenital Zika syndrome: An unexpected emerging arboviral disease. *J Inf Dis* 2016, (02) 011. ISSN 0163-4453 doi:10.1016/j.jinf.
 44. Buckley A, Gould EA. Detection of Virus-specific Antigen in the Nuclei or Nucleoli of Cells Infected with Zika or Langkat Virus. *J Gen Virol* 1988 69 (8): 1913–1920. doi:10.1099/0022-1317-69-8-1913. ISSN 0022-1317. PMID 2841406.
 45. CDC: Traveler's Health Outbreak Notice. Dengue, Tropical and Sub-tropical Region. <http://wwwnc.cdc.gov/travel/content/outbreak-notice/dengue-tropical-sub-tropical.aspx>
 46. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med*. 2009 Jun 11;360(24):2536-43. 6.
 47. Zammarchi L, Stella G, Mantella A, Bartolzzi D, Tappe D, Gunther S, et al. Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications. *J Clin Virol* February 2015 63: 32–35. doi:10.1016/j.jcv.2014.12.005. ISSN 1386-6532 PMID 25600600. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25600600>
 48. Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj, Mraz J, et al. (2016) Zika Virus Associated with Microcephaly. 2016, *N Eng J Med*, 374, 951-958. <https://doi.org/10.1056/NEJMoa1600651> (Accessed online Sept 2016)
 49. Michael SD: Understanding Zika virus Disease Pathogenesis; Washington University School of Medicine Departments of Medicine, Molecular Microbiology, Pathology & Immunology Center for Human Immunology and Immunotherapy Programs; NAS and NAM, Feb, 2016 Available at <https://pathology.wustl.edu/directory/robert-schreiber-phd/>
 50. Melo OAS, Malinger G, Ximenes R, Szejnfeld PO, Alves S, Bispo de FAM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound Obstet Gynecol*. 2016 Jan;47(1):6-7. DOI: 10.1002/uog.15831. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26731034>
 51. Pan American Health Organization, World Health Organization. Regional Office for the Americas. Epidemiological Alert: Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas [Internet]. Washington: World Health Organization; 2015 [updated 2015 Dec 1;

cited 2015 Dec 1]. Available at:

http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&Itemid=&gid=32405&lang=en.

52. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *CDC, Fort Collins, Colorado, USA; Emerging infectious diseases*. August 2008; 14(8):1232-9. Available at https://wwwnc.cdc.gov/eid/article/14/8/08-0287_article
53. Johnson N, Wakeley PR, Mansfield KL, McCracken F, Haxton B, Phipps LP, et al. Assessment of a novel real-time pan-flavivirus RT-polymerase chain reaction. *Vector borne and zoonotic diseases*. 2010 Oct;10(7):665-71. doi: 10.1089/vbz.2009.0210.
54. Patel P, Landt O, Kaiser M, Faye O, Koppe T, Lass U, et al. Development of one-step quantitative reverse transcription PCR for the rapid detection of flaviviruses. *J Virol* 2013;10:58. doi: 10.1186/1743-422X-10-58. Accessed May 2016
55. Centers for Disease Control and Prevention. Zika Virus. For Health Care Providers: Clinical Evaluation & Disease. January 2016. Available at http://www.cdc.gov/zika/hc/provider/clinical_evaluation.hmt
56. Sternberg S. Vaccine Efforts Underway as Zika Virus Spreads January 2016 US News & World Report. Available at http://www.usnews.com/news/articles/2016_01_22/vaccine_efforts_underway-as_zika_virus_spreads
57. Bagla P. How Bharat Biotech Made Its Breakthrough In Developing A Vaccine For Zika Virus. February, 2016). *Huffington Post (New Delhi)*. PTI. Available at http://www.huffingtonpost.in/2016/02/07/zika_virus_0_n_917977.html. Accessed January 2016. Accessed February 2016.
58. World Health Organization. WHO and experts prioritize vaccines, diagnostics and innovative vector control tools for Zika R&D. Available at www.who.int/medicine/news/note/2016/research-development-zika/en/ Accessed March 2016.